Stellar Biotechnologies - Independent KLH Toxicity & Immunogenicity Tests Complete
November 30, 2010
Port Hueneme, CA – Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) announces completion of preclinical toxicity and immunogenicity testing of Stellar KLH/SUBUNIT and Stellar KLH/IMG by independent laboratory, WuXi AppTech of St. Paul, MN (a wholly owned subsidiary of WuXi PharmaTech) in two preclinical studies, setting the stage for use of Stellar KLH/IMG in human studies.
Dr. Herbert Chow, VP Product Development, said, "Use of Stellar KLH as a potent adjuvant for immune stimulation, must be accomplished without causing increased susceptibility to infections, autoimmune reactions or immune suppression. The assessment of immunogenicity and immunotoxicity are therefore important steps for demonstrating safety in preclinical studies. In two separate pre-clinical studies, we have confirmed that Stellar KLH products, both our IMG and SUBUNIT forms, possess potent immune stimulatory effects with no observed safety or immunotoxicity problems. The data demonstrate the superiority of Stellar KLH/IMG as a dynamic adjuvant, and will support the regulatory filings leading to testing it in human studies."
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.
Darrell Brookstein, Executive VP
There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.